Compare FTCI & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | EVAX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 27.5M |
| IPO Year | 2021 | 2020 |
| Metric | FTCI | EVAX |
|---|---|---|
| Price | $1.63 | $2.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.20 | ★ $11.25 |
| AVG Volume (30 Days) | ★ 469.8K | 41.7K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,687,000.00 | N/A |
| Revenue This Year | $38.06 | N/A |
| Revenue Next Year | $58.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 110.51 | N/A |
| 52 Week Low | $1.62 | $2.72 |
| 52 Week High | $12.75 | $8.10 |
| Indicator | FTCI | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 28.40 | 36.60 |
| Support Level | N/A | N/A |
| Resistance Level | $2.86 | $3.62 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 1.39 | 20.63 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S.-manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.